| Literature DB >> 23744133 |
.
Abstract
A recent plea by oncologists condemning inflated prices for some cancer drugs has ignited a debate on this topic between clinicians and pharmaceutical companies and highlights the need for a broader assessment of drug valuation.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23744133 DOI： 10.1038/nm.3244
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440